Mackenzie Financial Corp Sells 1,530 Shares of Cencora, Inc. $COR

Mackenzie Financial Corp decreased its position in shares of Cencora, Inc. (NYSE:COR) by 0.9% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 174,863 shares of the company’s stock after selling 1,530 shares during the period. Mackenzie Financial Corp owned approximately 0.09% of Cencora worth $52,433,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Baader Bank Aktiengesellschaft lifted its holdings in shares of Cencora by 318.5% in the 2nd quarter. Baader Bank Aktiengesellschaft now owns 4,336 shares of the company’s stock worth $1,300,000 after buying an additional 3,300 shares during the period. Voleon Capital Management LP bought a new stake in shares of Cencora in the 1st quarter valued at about $3,111,000. Focus Partners Wealth lifted its position in shares of Cencora by 25.8% in the 1st quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock worth $1,589,000 after purchasing an additional 1,171 shares during the period. Acadian Asset Management LLC boosted its stake in shares of Cencora by 947.5% during the second quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock valued at $77,069,000 after purchasing an additional 232,539 shares in the last quarter. Finally, Martin Capital Partners LLC increased its holdings in Cencora by 205.2% during the second quarter. Martin Capital Partners LLC now owns 3,784 shares of the company’s stock valued at $1,135,000 after buying an additional 2,544 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Trading Up 0.1%

Cencora stock opened at $368.93 on Monday. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. The stock has a market cap of $71.53 billion, a PE ratio of 37.96, a price-to-earnings-growth ratio of 1.56 and a beta of 0.63. The stock has a 50-day moving average of $335.71 and a two-hundred day moving average of $307.83. Cencora, Inc. has a one year low of $223.92 and a one year high of $377.54.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. The business had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company’s revenue was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio (DPR) is currently 30.19%.

Analysts Set New Price Targets

A number of analysts have weighed in on COR shares. UBS Group upped their target price on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Weiss Ratings restated a “buy (b-)” rating on shares of Cencora in a research note on Tuesday, November 25th. Evercore ISI set a $400.00 price objective on Cencora and gave the company an “outperform” rating in a research report on Thursday, November 6th. Robert W. Baird boosted their target price on shares of Cencora from $355.00 to $395.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Finally, Mizuho increased their price target on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $371.09.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 31,350 shares of Cencora stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the sale, the chairman directly owned 305,913 shares in the company, valued at approximately $88,671,942.18. The trade was a 9.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction on Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the sale, the chief executive officer directly owned 37,940 shares in the company, valued at $12,398,792. This trade represents a 11.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 46,640 shares of company stock valued at $14,099,338. Corporate insiders own 10.80% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.